Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Squalamine selected for Pilot 2

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

FDA taps Genaera's anti-angiogenic squalamine for its Continuous Marketing Application Pilot 2 program, the firm announces Jan. 4. Squalamine was selected by CDER's Division of Anti-Inflammatory, Analgesic and Ophthalmic Drug Products; the program provides frequent scientific feedback and interaction during the IND phase, with each review division choosing one participant. Squalamine is being developed for "wet" age-related macular degeneration. Phase II trials are underway, with data expected in the first quarter. Genaera plans to begin Phase III in the first half of 2005, to run concurrently with its largest Phase II study...
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS002773

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel